Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Ophthalmology
Published in: International Ophthalmology 2/2017

01-04-2017 | Original Paper

Bromfenac ophthalmic solution 0.09 %: human aqueous humor concentration detected by high-performance liquid chromatography

Authors: Angelo Macrì, Aldo Vagge, Annalisa Salis, Carmen Fucile, Valeria Marini, Antonietta Martelli, Sebastiano Giuffrida, Michele Iester, Gianluca Damonte, Francesca Mattioli

Published in: International Ophthalmology | Issue 2/2017

Login to get access

Abstract

The purpose of this study was to evaluate the aqueous humor concentrations of bromfenac ophthalmic solution 0.09 % in patients undergoing phacoemulsification. Patients requiring cataract extraction received one drop (50 µL) of bromfenac 0.09 % solution in the eye to be operated, before bedtime the day before surgery or the morning of the surgery. The last administration was recorded. At the time of paracentesis, an aqueous humor sample was collected with a 30-gauge needle attached to a TB syringe and was later analyzed by high-performance liquid chromatography for drug concentration. 188 treated volunteers and 48 control, untreated, subjects were included in the study. The mean aqueous concentration of bromfenac in the treated group was 37.60 ± 68.86 and 0 nM (nmol/L) in the control group (p < 0.0001). Correlation coefficient in bromfenac group between time elapsed from instillation and drug concentration was −0.16 (p not significant). Bromfenac showed properties of good penetration and stable concentration in aqueous humor up to about 12 h after instillation.
Literature
1.
Gupta S, Khurana AK, Ahluwalia BK, Gupta NC (1991) Topical indomethacin for vernal keratoconjunctivitis. Acta Ophthalmol 69:95–98CrossRef
2.
Laibovitz RA, Koester J, Schaich L et al (1995) Safety and efficacy of diclofenac sodium 0.1% ophthalmic solution in acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 11:361–368CrossRefPubMed
3.
Tauber J, Raizman MB, Ostrov CS et al (1998) A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 14:137–145CrossRefPubMed
4.
Donnenfeld ED, Perry HD, Wittpenn JR et al (2006) Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve. J Cataract Refract Surg 32:1474–1482CrossRefPubMed
5.
Roberts CW (1996) Pretreatment with topical diclofenac sodium to decrease postoperative inflammation. Ophthalmology 103:636–639CrossRefPubMed
6.
Yavas GF, Ozturk F, Kusbeci T (2007) Preoperative topical indomethacin to prevent pseudophakic cystoid macular edema. J Cataract Refract Surg 33:804–807CrossRefPubMed
7.
Kessel L, Kendal B, Jorgensen KJ et al (2014) Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology 121(10):1915–1924CrossRefPubMed
8.
Renfro L, Snow JS (1992) Ocular effects of topical and systemic steroids. Dermatol Clin 10(3):505–512PubMed
9.
10.
ESCRS Endophthalmitis Study Group (2007) Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg 33:978–988CrossRef
11.
12.
Bucci FA Jr, Waterbury LD (2011) Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification. Adv Ther 28(12):1089–1095CrossRefPubMed
13.
Baklayan GA, Muñoz M (2014) The ocular distribution of (14)C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model. Clin Ophthalmol 8:1717–1724CrossRefPubMedPubMedCentral
14.
Oka T, Shearer T, Azuma M (2004) Involvement of cyclooxygenase-2 in rat models of conjunctivitis. Curr Eye Res 29(1):27–34CrossRefPubMed
15.
Miyamoto T, Saika S, Okada Y et al (2004) Expression of cyclooxygenase-2 in corneal cells after photorefractive keratectomy and laser in situ keratomileusis in rabbits. J Cataract Refract Surg 30(12):2612–2617CrossRefPubMed
16.
Radi ZA, Render JA. The pathophysiologic role of cyclo-oxygenases in the eye. J Ocul Pharmacol Ther. 2008;24(2):141–151)
17.
Ruiz J, López M, Milà J et al (1993) QSAR and conformational analysis of the anti-inflammatory agent amfenac and analogues. J Comput Aided Mol Des 7(2):183–198CrossRefPubMed
18.
Baklayan GA, Patterson HM, Song CK et al (2008) 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther 24(4):392–398CrossRefPubMed
19.
Macri A, Marini V, Sangalli G et al (2015) An artificial aqueous humor as a standard matrix to assess drug concentration in the anterior chamber by high performance liquid chromatography methods. Clin Lab 61(1–2):47–52PubMed
20.
Miyake K (1977) Prevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary report. Albrecht Von Graefes Arch Klin Exp Ophthalmol 203(2):81–88CrossRefPubMed
21.
Kraff MC, Sanders DR, Jampol LM et al (1982) Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology 89(8):885–890CrossRefPubMed
22.
Flach AJ (1998) The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 96:557–634PubMedPubMedCentral
23.
Rossetti L, Chaudhuri J, Dickersin K (1998) Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. Results Meta Anal Ophthalmol 105(3):397–405
24.
Rho DS (2003) Treatment of acute pseudophakic cystoid macular edema: Diclofenac versus ketorolac. J Cataract Refract Surg 29(12):2378–2384CrossRefPubMed
25.
Yannuzzi LA, Landau AN, Turtz AI (1981) Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology 88(9):947–954CrossRefPubMed
26.
Friedlaender MH (2001) The current and future therapy of allergic conjunctivitis. Curr Opin Ophthalmol 1:375–379
27.
28.
Badalà F, Fioretto M, Macrì A (2004) Effect of topical 0.1% Indomethacin solution versus 0.1% Fluorometholon on ocular surface and pain control following Laser Subepithelial Keratomileusis (LASEK). Cornea 23(6):550–553CrossRefPubMed
29.
Zanetti FR, Fulco EA, Chaves FR et al (2012) Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: a randomized trial. Indian J Ophthalmol 60(4):277–281CrossRefPubMedPubMedCentral
30.
Gayton J (2009) Concentration and dosing of ketorolac versus bromfenac. J Cataract Refract Surg 35(7):1319CrossRefPubMed
31.
Gluud BS, Jensen OL, Krogh E et al (1985) Prostaglandin E2 level in tears during postoperative inflammation of the eye. Acta Ophthalmol 63(4):375–379CrossRef
32.
Yanni JM, Graff G, Hellberg MR (1995) Adminstering 3-benzoylphenylacetamide derivatives. United States patent US5475034
33.
Miyake K, Ogawa T, Tajika T et al (2008) Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor. J Ocul Pharmacol Ther 24(6):573–578CrossRefPubMed
Metadata
Title
Bromfenac ophthalmic solution 0.09 %: human aqueous humor concentration detected by high-performance liquid chromatography
Authors
Angelo Macrì
Aldo Vagge
Annalisa Salis
Carmen Fucile
Valeria Marini
Antonietta Martelli
Sebastiano Giuffrida
Michele Iester
Gianluca Damonte
Francesca Mattioli
Publication date
01-04-2017
Publisher
Springer Netherlands
Published in
International Ophthalmology / Issue 2/2017
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-016-0279-3

Other articles of this Issue 2/2017

International Ophthalmology 2/2017 Go to the issue

Original Paper

Comparison of pain experience during 23-G vitreoretinal surgery under topical and retrobulbar anesthesia

Original Paper

Inner retinal thinning after Brilliant Blue G-assisted internal limiting membrane peeling for vitreoretinal interface disorders

Original Paper

Safety and complications of intravitreal injections performed in an Asian population in Singapore

Perspectives or Expert Opinions

Two-spatulae maneuver to intraocularly flip a reverse-opened, foldable intraocular lens

Original Paper

A novel method to reduce noise in electroretinography using skin electrodes: a study of noise level, inter-session variability, and reproducibility

Original Paper

Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations